Method of treating knee arthritis

FIELD: food-processing industry.

SUBSTANCE: treatment is preceded by measuring a blood lymphocyte percentage. If the measured value is more than 35%, that is combined with point massage and administration of acyclovir. The point massage is performed with fingers. The points IV.9, XI.34, VII.60, III.36 are exposed. The 10-day therapeutic course of acyclovir administration is prescribed. Acyclovir is administered in a dose of 400mg 4 times a day.

EFFECT: relieving clinical manifestations of arthritis, reducing time of treatment taking into account the immune state.

3 ex

 

The invention relates to medicine, namely to traumatology and infectious diseases.

Currently, the treatment of various diseases with impact on biologically active points received widespread distribution.

This method improves microcirculation in many organs and systems, analgesic and antiseptic effects primarily on smooth muscles, improves immunity and the body's resistance to infections, affects the production of neurohumoral substances, has a pronounced anti-depressive and sedative effects (E. L. Macheret, I. H. Samosyuk, B. N., Lysenok. Reflexology in the treatment of diseases of the nervous system. - K.: Health, 1989. - 232 S.).

There is a method of treatment of juvenile rheumatoid arthritis, namely, what is the impact of pulsed laser radiation 4 watts with a wavelength of 0.89-0.95 microns, contact, within 16 each, with the point total of the impact on YG-20 daily, GJ-4, ΥΒ-20, E-36, Υ-40 days and local points located in the area of the affected joints, when monoarthritis interact daily with arthritis through the day (E. A. Shlapak, S. N. Evseeva, N. T. Gabitova, H. K. Apanasevich, L. N. Shvedunov. The method of treatment of juvenile rheumatoid arthritis. RF patent for the invention №2072825 from 20.02.1997) (anal is g)).

The disadvantages of this method include the use for the treatment of expensive laser device PATTERN, the use of a large number of acupuncture points and treatment without regard to infectious origin of the disease. The most important is the treatment of a narrow circle of persons (children) with strictly the particular case of a joint injury, namely rheumatoid. Meanwhile, the reasons for the defeat of joints, including the knee, is very diverse.

The closest to the technical nature of the claimed is a method of treating arthritis of the knee, including finger acupressure points IV.9, XI.34 VII.60, III.36 (C. K. Makarov, Muhammad Al-Hosen. Help yourself. Tutorial on acupressure. Tver. - 2000. - S. 13 (prototype)).

The disadvantage of this method is that the treatment of arthritis of the knee is carried out without taking into account the state of immunoreactivity in the development and progression of the disease.

In the claimed invention solves the task of expanding Arsenal of ways to treat arthritis of the knee.

The technical result - the reduction of clinical symptoms of arthritis of the knee in the acute phase or in the acute stage taking into account the state of immunoreactivity.

This technical result is achieved in that in the method of treatment of arthritis of the knee by finger acupressure points IV.9, XI.34 VII.60, III.36 in which Alceste 7 sessions before treatment to determine the percentage of lymphocytes in the blood and when their value is higher than 35% at the same time spend a 10-day course of treatment with acyclovir at a dose of 400 mg 4 times a day.

The level of lymphocytes above 35% selected based on what is known, what percentage of healthy individuals amounts to 30.3±0,5% (C. K. Makarov. Features leukocyte blood in patients with alcohol / Provincial medical news, 2002. - so 5, vol.1. - S. 25-27).

New, previously unknown features of the claimed method of treatment of arthritis of the knee are:

1. use as chemotherapy drugs acyclovir allowed to reveal new properties of acyclovir that result significantly increased the effectiveness of the treatment of resistant forms of the disease;

2. using a simple objective test for the diagnosis of individual indications for prescription of acyclovir;

3. the purpose of acyclovir in acute period of the disease, immediately after the treatment the patient for treatment;

4. developed and proposed levels of lymphocytes, rejecting upward beyond which the patient simultaneously treatment finger acupressure administered acyclovir;

5. the dependence of the efficiency from the use of acyclovir with the percentage of lymphocytes per ml of peripheral blood, i.e. when the interest rate of lymphocytes above 35% in both treatment finger acupressure administered acyclovir.

The method was developed on the basis of the results of treatment of 20 patients with arthritis of the knee, the item is receive emitting only therapy in the form of acupressure and 30 patients with arthritis of the knee, which combination therapy was carried out simultaneously with the treatment finger acupressure conducted 7 sessions of acupressure points IV.9, XI.34 VII.60, III.36 and 10-day course of treatment with acyclovir at a dose of 400 mg 4 times a day.

Average of 35% of the lymphocytes are the most common top level of their values examined as a control of 30 healthy men aged from 18 to 60 years. The increase in the relative content of lymphocytes (lymphocytosis) is typical for a normal immune response in viral diseases (patent No. 2171989 from 10.08.2001). Hence, based on the reverse, if the patient has even a slight lymphocytosis, it was possible to suggest a viral etiology of the disease.

Why was applied for the treatment of antiherpetic drug ACYCLOVIR in the hope that it will have a therapeutic effect on other viruses. ACYCLOVIR was chosen for the following main reasons:

1. the drug is many times cheaper than used for the treatment of viral diseases preparations of recombinant interferon (intron a, realigion, Avonex, Betaferon, IFN, Roferon and others);

2. the drug is well tolerated and no side effects, whereas the use of recombinant interferons often on the skin and mucous appeared herpetic with the ro, increased body temperature up to 39°C.

The method is carried out in the following sequence. After treatment of the patient with arthritis of the knee prescribed examinations, including complete blood count. When identifying a patient with arthritis of the knee the percentage of lymphocytes more than 35% at the same time spend 7 sessions of acupressure points IV.9, XI.34 VII.60, III.36 and 10-day course of treatment with acyclovir at a dose of 400 mg 4 times a day. After treatment, re-define indicators of clinical blood analysis, including lymphocytes. When reducing the percentage of lymphocytes in comparison to the original patient's consider the effect of treatment with acyclovir is positive.

Example 1.

The patient is gg 62 years appealed to the infectious disease specialist about arthritis of the left knee. During the month repeatedly has received antibiotics. The effect was unstable and short-lived. In the blood content of lymphocytes was 37%, which is more than 35% of predicted viral etiology of the disease was the indication for use of acyclovir. There were 7 sessions finger acupressure and a ten-day course of treatment with acyclovir at a dose of 400 mg 4 times a day. The result was the cure. Pain and swelling of the joints disappeared, the movement has recovered in full. During the examination in the course of treatment was confirmed by viral PR is kind of diseases.

Example 2. Patient Makarova M. C. 24 years appealed to the infectious disease specialist about arthritis knee of the right leg. Traumatologists held puncture of the knee joint and remove excess synovial fluid. However, one week later resurfaced knee pain, swelling, stiffness. In the blood content of lymphocytes was 39%, which is more than 35% of predicted viral etiology of the disease was the indication for use of acyclovir. There were 7 sessions finger acupressure and a ten-day course of treatment with acyclovir at a dose of 400 mg 4 times a day. The result was the cure. Pain and swelling of the joints disappeared, the movement has recovered in full. During the examination in the course of treatment was confirmed by the viral nature of the disease.

Example 3. Patient Shamshiev, A. R. 43 years appealed to the infectious disease specialist about arthritis knee of the right leg. During the week received antibiotics. Without effect. In the blood content of lymphocytes was 42%, which is more than 35% of predicted viral etiology of the disease was the indication for use of acyclovir. There were 7 sessions finger acupressure and a ten-day course of treatment with acyclovir at a dose of 400 mg 4 times a day. The result was the cure. Pain and swelling of the joints disappeared, the movement has recovered in full. When a survey is assured in the course of treatment was confirmed by the viral nature of the disease.

This method is simple, high efficiency, reduces the number of days of work incapacity, i.e. brings clear economic benefits available in the practice of surgeons and infectious disease specialists, you can restore the physical and mental health of patients in connection with the disappearance of pain in the knee, recovery of motor abilities, does not require expensive equipment, can be executed in any institution, contributes to the effectiveness of treatment of patients with arthritis of the knee viral etiologii.

A method of treating arthritis knee viral etiology, which includes 7 sessions finger acupressure points IV.9, XI.34 VII.60, III.36, characterized in that before treatment in patients determine the percentage of lymphocytes in the blood and when their value is higher than 35% at the same time spend a 10-day course of treatment with acyclovir at a dose of 400 mg 4 times a day.



 

Same patents:

FIELD: medicine.

SUBSTANCE: according to the method, the affected joints are exposed. The exposure is performed by electrophoresis with 2% pentoxifylline. The pentoxifylline solution is introduced from an anode at current intensity 15 mA. The 15-minute introduction is performed at current density 0.05-0.1 mA/cm2. The therapeutic course is 10 procedures.

EFFECT: method is non-invasive, easy to implement; it reduces the length of treatment.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents pharmaceutical depot, made for introduction by intra-articular injection into joint of subject, suffering from osteoarthritis, which contains microparticles or nanoparticles, composed of N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-[pyridin-2-ylmethoxy)benzamide or its pharmaceutically acceptable salt and biodegradable copolymer lactic acid-glycolic acid.

EFFECT: invention provides controlled release of active agent and long action without toxic side effects.

13 cl, 5 ex, 3 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: invention represents a drug for treating osteoarthrosis presented as a soft dosage form, containing glucosamine and methyl salicylate as active substances, and additive agents.

EFFECT: enhanced anaesthetic action and lower toxicity of methyl salicylate.

10 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: composite application of therapeutic preparations is combined with a laser therapy. A basic anti-inflammatory preparation is presented by methotrexate administered subcutaneously in a dose of 15mg once a week, and folic acid administered orally in a dose of 5mg a week. Movalis is additionally prescribed in the form of intramuscular injections in a dose of 15mg once a day. The laser therapy is differentiated depending on a degree of the disease, a degree of endothelial dysfunction manifestation, namely a von Willebrand factor (vWF), haemostasis system activity indices, namely activated partial thromboplastin time (APTT), prothrombin time (PTT), thrombin clotting time (TCT), antithrombin III (AT III), protein C. If observing the degree I of the disease, APTT 30.6±1.5 sec or more, PTT 19.2±0.9 sec or more, TCT 15.1±0.7 sec or more, AT III 92.8±7.6% or more, protein C 0.92±0.02 or more, vWF 108.9±9.6% or less, 6-8 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at a light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day. The degrees II and III of the disease, APTT 22.2±5.5 sec or less, PTT 12.8±1.7 sec or less, TCT 11.2±0.9 sec or less, AT III 85.4±1.1% or less, protein C 0.84±0.02 and less, vWF 133.5±2.2% or more, require performing 10 daily procedures of the intravenous laser blood irradiation, on the first day for 15 minutes at wavelength 0.365mcm, on the following day for 5 minutes at wavelength 0.405mcm, radiant power at the light guide end 1.5-2.0mV in a continuous mode; the procedures are alternated every second day.

EFFECT: method enables reducing the clinical manifestations of the disease, provides higher effectiveness of the drug therapy by involving the pathological processes in the haemostasis system.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula IV, VIII-A and X, and to their pharmaceutical acceptable salts possessing the inhibitory activity on PI3-kinase (phosphoinositide-3-kinase). In compounds of formula IV and IX and Wd is specified in a group consisting of, , , and each of which can be substituted. In formula VIII-A, the group Wd represents the group or , wherein Ra is hydrogen, R11 is amino; in compound IV, Wa2 represents CR5; Wa3 represents CR6; Wa4 represents N or CR7; in compound IX, Wa1 and Wa2 independently represent CR5, N or NR4, and Wa4 independently represents CR7 or S, wherein no more than two neighbouring atoms in a ring represent atom or sulphur; Wb5 represents N; B represents a grouping of formula II, as well as in case of compound IV, B means C1-C10alkyl, C3-C10cycloalkyl, C3-C10heterocycloalkyl having one to six ring heteroatoms specified in N, O and S; in case of compound IX, B also means C1-C10alkyl, C3-C10cycloalkyl or 6-merous heterocycloalkyl having nitrogen atom; Wc represents C6-C10aryl or 5-18-merous heteroaryl having one or more ring heteroatoms specified in N, O and S, or phenyl or 6-merous heteroaryl respectively is equal to an integer of 0, 1, 2, 3 or 4; X is absent or represents -(CH(R9))z-, respectively; z is equal to 1; Y is absent. The other radical values are specified in the patent claim.

EFFECT: compounds can be used for treating such diseases, as cancer, bone disorders, an inflammatory or immune disease, diseases of the nervous system, metabolic disorders, respiratory diseases, thrombosis or cardiac diseases mediated by PI3-kinase.

68 cl, 11 dwg, 7 tbl, 55 ex

FIELD: medicine.

SUBSTANCE: composition 16-21ml consisting of a mixture of therapeutic preparations: Dona glucosamine sulphate 3.0 ml; ChondroGuard, or Mucosatum, or Chondrolon chondroitin sulphate - 2.0 ml; Alflutop 2.0 ml; Actovegin 4.0-5.0 ml; glucocorticosteroids Depo-Medrol 1.0-2.0 ml in the concentration of 40 mg/ml, or Diprospane 1.0-2.0 ml in the concentration of 7 mg/ml, or Metipred 1.0-2.0 ml in the concentration of 62.5 mg/ml; vitamins B1, B6, B12 Combilipen 2.0 ml, or Milgamma 2.0 ml, or Neurobion 3.0 ml; 95% or 70% ethanol 2.0-4.0 ml, is administered into a pathologically changed region. That is immediately followed by exposing the pathologically changed region and adjoining segments to a session of A shock-wave therapy in the following mode: pressure 1.2 - 4.0 bar, frequency 7-12 Hz, beat quantity 8000-14000 for 20-40 minutes. The complex procedures are performed within the course of 1-6 times every 7-10 days.

EFFECT: method enables the direct exposure on the pathologically changed region to achieve the optimum concentration of drug preparations therein with avoiding systemic prescription and preventing a risk of side effects.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of general formula [1] or their pharmaceutically acceptable salts, which possess properties of an inhibitor of the JAK2 thyrokinase activity. In general formula radicals are selected from group (I) or (II). In group (I) X represents CH or N; R1 represents a halogen atom and R2 represents H, a halogen atom, CN, or is selected from the groups of formulas

,

or a group -ORP or 5-6-membered heteroaryl, containing 1-4 nitrogen atoms and optionally additionally containing an oxygen or sulphur atom or containing an oxygen atom as a heteroatom, optionally substituted; or (II) X represents -CRA; and RA represents a group of formula , RB represents (a) amino, optionally substituted with one or two groups, selected from the group, consisting of C1-6alkyl, C3-6cycloalkyl, (C3-6cycloalkyl)C1-6alkyl and C1-3alcoxyC1-3alkyl, (b) C1-3alcoxy, (c) hydroxy or (d) a 5-6-membered saturated cyclic amino group, which additionally can contain a heteroatom, selected from an oxygen atom; R1 represents a halogen atom and R2 represents H; R3 -R5 have values given above. Other values of the radicals are given in the invention formula.

EFFECT: compounds can be applied for the prevention or treatment of cancer, for instance hematologic cancer disease or a solid form of cancer, inflammatory disorder, for instance, rheumatoid arthritis, inflammatory intestinal disease, osteoporosis or multiple sclerosis and angiopathy, for instance, pulmonary hypertension, arteriosclerosis, aneurism or varicose veins.

14 cl, 19 tbl, 234 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises intravenous injection of 3-5.5% aqueous solution of lithium chloride based on 2.5-3.5 mmol/kg of animal body weight, and additionally subcutaneously 10-30% aqueous solution of polyethylene glycol-4000 based on 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: increased efficiency and simplification of the method.

4 ex

FIELD: veterinary medicine.

SUBSTANCE: method of treatment of intervertebral disk disease in dogs comprises administering the medicinal product, and the medicinal product is used as 10-30% aqueous solution of polyethylene glycol-4000, which is administered subcutaneously in an amount of 2-4 ml/kg of animal body weight every second day for 5-7 days.

EFFECT: improvement of efficiency of the method.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of general formula (I), possessing an activity with respect to cytokines, versions of based on them pharmaceutical compositions and their application. Formula (I) compounds can be applied for treatment or prevention asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis or gouty arthritis. In general formula (I) L is selected from the group, consisting of -C(O)-, -CH2-, Ar1 represents a mono-, di- or trisubstituted phenyl ring, where substituents are independently selected from the group, consisting of a halogen and -C1-4alkyl; Ar2 represents an optionally substituted thiadiazolyl ring, where the substituent represents -C1-4alkyl, -C3-5cycloalkyl, -methylcyclopropyl, phenyl or a 5- or 6-membered monocyclic heteroaromatic ring or a bicyclic heteroaromatic ring with 9 or 10 atoms, with the said heteroaromatic ring containing 1, 2 or 3 heteroatoms, selected from the group, consisting of S, O and N, where the said phenyl or heteroaromatic ring is optionally mono- or disubstituted with substituents, independently selected from the group, consisting of a halogen, -C1-6alkyl, optionally substituted with 1-4 fluorine atoms, -O-C1-6alkyl, -CF3 and oxo.

EFFECT: increased efficiency of the application of the compounds.

16 cl, 1 tbl, 46 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and maxillofacial surgery, and can be applied for treating affection of vegetative parasympathetic nodes of head of herpes-virus etiology. For this purpose introduced are: famciclovirum in dose 500 mg 3 times per day for 10 days, ketorop in dose 1 tablet 2 times per day after meal for 7 days, tavegyl in dose 1 tablet 1 time per day before going to bed for 10 days, neuromultivit in dose 1 tablet 2 times per day for 30 days, in addition, additionally introduced is viferon in form of rectal suppositories in dose 1 suppository (500000) 1 time per day for 10 days. Patient takes all medications mentioned above simultaneously. When the course of viferon intake is over, cycloferon in tablets is administered in tablets with dose 150 mg with the schedule of intake as follows: 1-st day - 1 tablet 2 times per day; 2-nd day - 1 tablet 1 time per day; 4, 6, 8, 11, 14, 17, 20, 23-rd day - 1 tablet 1 time per day, after intake of which administered is immunorm in dose 1 tablet 3 times per day for 30 days.

EFFECT: method makes it possible to increase therapeutic effect due to simultaneous impact on herpes virus and separate links of immunity with increase of remission and reduction of term of its development, absence of aggravations and long support of organism and virus equilibrium.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology and concerns improving t mental activity of trainees. That is ensured by daily administration of caffeine 0.2 g followed by self-massage of the head and neck. Self-massage involves performing stroking, compression and rubbing spiral motions started from the head periphery from the back to front scalp border. That is followed by self-massage of the cervical region started with stroking motions from the shoulder joint to the scalp, then pressing up motions in the same direction and rubbing motions circularly with four fingers from the shoulder joint to the occipital bone. Self-massage of the head and neck finally involves stroking motions.

EFFECT: combined effect of caffeine in the declared dose and self-massage according to the developed technique provides higher mental capacity that is particularly expressed by better thinking and aptitude, as well as the quality of the operator performance elements.

1 tbl

FIELD: medicine.

SUBSTANCE: haemostatic values, endothelial dysfunction characteristics, diagnosed genetic forms of thrombophilia and habitual miscarriage are detected; the detected disorders are assessed in points depending on the gestational age. That is followed by calculating the total score, and therapy is prescribed depending on the total score. The case follow-up involves changing the therapeutic regimen with the total score variations.

EFFECT: method enables assessing objectively and standardising the therapeutic options in thrombophilic disorders accompanying pregnancy.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a compound having a structure according to formula I:

,

compositions containing the compounds of the above formula applicable to stimulate neurogenesis and/or inhibition of neuron degeneration.

EFFECT: invention may be used in treating diseases and conditions characterised by neuron loss and lower neurogenesis, including Alzheimer's disease, stroke, traumatic brain injury, traumatic nerve injury and depression.

8 cl, 2 tbl, 2 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents an agent consisting of theobromine and a non-opiate antitussive agent representing an NMDA antagonist in the form of a combination preparation for treating cough.

EFFECT: invention provides a synergetic effect on cough suppression and improved clinical effectiveness in cough treatment.

20 cl, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing acyclovir 2/3 hydrate, which involves mixing acyclovir with water in weight ratio of 1:5-50, dissolving at 50-100°C, filtering, cooling the filtrate at 0-30° to deposit crystals, collecting crystals by filtering and drying the crystals at 0-150°C for 0.5-24 hours to obtain acyclovir 2/3 hydrate having a stable crystalline structure.

EFFECT: preparation process is simple and suitable for industrial production.

10 cl, 4 dwg, 1 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: present invention refers to a prolonged release tablet containing theobromine and comprising a prolonged release layer and a fast release layer, wherein the prolonged release layer consists of 40-60 wt % of theobromine as an active ingredient and 14-19 wt % of a prolonged release base consisting of polyethylene oxide and hydroxypropyl methylcellulose, and the fast release layer consists of 10-30 wt % of theobromine as an active ingredient and 0.5-2 wt % of an aerating agent consisting of one or more ingredients specified in croscarmellose sodium, crospovidone and starch glycolate sodium salt.

EFFECT: prolonged release tablet according to the present invention effectively suppresses various types of cough symptoms if taken only once a day.

4 cl, 2 dwg, 4 tbl

FIELD: biotechnologies.

SUBSTANCE: invention refers to cyclohexyl ammonium salt of 2-[3-methyl-7-(1,1-dioxotiethanyl-3)-1-ethyl xanthenyl-8-tio]acetic acid of the following formula: .

EFFECT: obtaining a new compound that shows antithromboembolic action and can be used in medicine.

2 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely resuscitation and intensive care, and may be used in treating a craniocerebral injury. That is ensured by administering dexamethasone 0.3 ml and trental 0.4 ml into an inferior external orbital angle between an eyeball and a bone orbit, external and inferior rectus muscle of eye with underlying standard drug-induced therapy. The introduction is once a day daily for 5-7 days.

EFFECT: method provides the highest drug concentrations in the cerebral tissues once administered into the retrobulbar space over a shorter period of time than if administered otherwise that in turn leads to faster cerebral decongestion, peripapillar optic nerve decongestion, and as a consequence ensures faster coming out of coma of the patient with the craniocerebral injury.

3 ex

FIELD: medicine.

SUBSTANCE: dermal flap is simulated in laboratory animals on the second day of experiment. Sildenafil 2.2 mg/kg is introduced intraperitoneally on the first, third and fifth day of the experiment.

EFFECT: dermal flap survival rate in reduced circulation with no side effects.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves the exposure of biologically active points (BAPs), the intake of herbal teas, the conflict management and the compliance with sleep mode. The BAPs exposure is conducted by finger pressing and twisting. The exposure takes the first 10 days of the therapeutic course. The exposure length is 3-5 minutes and involves the finger pressing and clockwise twisting in the moderating rhythm. On the odd-numbered day, the exposure covers a group of points found on the meridians, including a posterior median one - one point, an anterior median one - two points, a spleen - a pancreas - one point, a stomach - one point, lungs - one point, a liver - one point, kidneys - one point, and an urinary bladder - one point. On the even-numbered day, the exposure covers a group of points found on the meridians, including a posterior median one - one point, an anterior median one - two points, a spleen - a pancreas - one point, lungs - one point, a liver - one point, kidneys - one point, and an urinary bladder - two points. The whole therapeutic course is of the length of 3.5-4.0 months; in the first two months, herbal tea of milfoil is taken, while in the second two months - herbal teas of centaury and St. John's wort. The therapeutic course is accompanied by complying with the general and water schedules.

EFFECT: method provides the higher clinical effectiveness ensured by avoiding the psychological rejection of the conducted treatment and creating the health memory in the children.

5 cl, 3 ex

Up!